ARTICLE | Finance
Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting
Start-up obtains S1PR modulator from Kyorin
A VC syndicate is backing Priothera with a €30 million ($35.5 million) series A round to develop a clinical S1PR modulator for acute myelogenous leukemia patients undergoing hematopoietic stem cell transplantation.
The group believes mocravimod, which Priothera Ltd. has acquired from Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), can be a best-in-class therapy for AML...